register

News & Trends - Pharmaceuticals

‘Significant breakthrough’ as first adjuvant immunotherapy is PBS listed for gastro-oesophageal cancers

Health Industry Hub | March 30, 2023 |

Pharma News: The first adjuvant immunotherapy reimbursed for resected oesophageal cancer (OC) or gastro-oesophageal junction cancer (GOJC) in patients who have received neoadjuvant chemoradiotherapy (CRT) will be listed on the Pharmaceutical Benefits Scheme (PBS) effective 1 April.

BMS’ Opdivo (nivolumab) PBS listing is supported by positive data from the Phase 3 CheckMate 577 trial in which Opdivo treatment in OC and GOJC patients following trimodality therapy (neoadjuvant CRT and complete surgical resection) doubled disease-free survival (DFS) compared to placebo. The median DFS in Opdivo-treated patients was 22.4 months compared to 11.0 months in the placebo group.

According to Medical Oncologist, Professor Stephen Clarke OAM, GenesisCare North Shore, the reimbursement of the first adjuvant immunotherapy option for this patient group represents a significant breakthrough in gastro-oesophageal cancer care.

“While patients who present with operable disease can have trimodality therapy, disease recurrence is common. There is a particularly high risk of recurrence for the up to 75% of patients whose tumours do not show a complete therapeutic response. In the absence of adjuvant treatment options, clinicians have historically used a ‘wait and watch’ approach after treatment failure in the neo-adjuvant setting,” said Prof Clarke.

“The reimbursement of an adjuvant immunotherapy option for this patient population is welcomed news and represents a significant milestone in addressing this high clinical unmet need.”

Clinicians welcome expanded indication for BMS’ melanoma treatment

Gastro-oesophageal cancers are a heterogenous group encompassing distinct histologic and genomic subtypes that can arise in the oesophagus, stomach or the junction between these organs. Patients with gastro-oesophageal cancers typically face significant quality of life impacts due to impaired physical activity, fatigue, insomnia, mental health decline, and pain.

In 2022, approximately 2,572 Australians were newly diagnosed with stomach cancer (including a subset of GOJC), with 1,146 Australians dying of the disease. For OC, these numbers were estimated at 1,725 new cases and 1,394 deaths in 2022.

Medical Director of Bristol-Myers Squibb Australia and New Zealand, Dr Melinda Munns, said the company is committed to leading innovative science in earlier stages of cancer with the goal of disrupting the course of the disease.

“The listing follows from the reimbursement for Opdivo in later stages of gastro-oesophageal cancer. BMS was the first company to bring checkpoint inhibitors to patients with oesophagogastric cancer, and we are pleased to be the first to bring adjuvant therapy to Australian patients with oesophageal or gastro-esophageal junction cancers who continue to face a high unmet need.

“Recurrence often marks the transition from curable to incurable disease and represents a life-altering event for patients. We believe intervening in earlier stages of cancer may interrupt this trajectory, helping patients live longer and with a higher quality of life as we work toward a cure,” said Dr Munns.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.